For the third straight quarter in a row, OmniComm Systems, a leader in integrated electronic data capture solutions for clinical trials, is reporting another landmark quarter for new business. The company has surpassed its previous best quarter and signed contracts through the first two quarters of 2008 totaling almost $12 million, which surpass all of the revenues brought in from last year’s signed contracts.

During the second quarter, OmniComm signed a long-term guaranteed contract with a major biotechnology company which helped to boost the company’s financials. They have also continued to increase their customer base by adding seven new clients to their customer list, and continue to see recurring business from their existing loyal customers, who have added five more trials. Finally, they have added six new partners to their very successful Preferred Partnership Programs.

“I couldn’t be happier with the current momentum and speed in which we continue to

TapImmune, Inc. (OTCBB: TPIM) announced that their TAP incorporated vaccine for the treatment of cancer was recently reviewed by a third party research article in the Journal of Investigative Dermatology, which confirmed that the company’s vaccine should be considered as a therapy for cancer.

The article, entitled, “Restoration of the Expression of Transporters Associate with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity,” was published in advance online on April 3, 2008. TapImmune is a biotechnology company that specializes in the development of immunotherapeutics for cancer and vaccines for infectious diseases, and the company’s stock rose 37.10% in Monday’s trading.

The company’s promising TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. TAP, which stands for Transporters with Antigen Processing, are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without

Viral Genetics Inc. is a biotechnology company with a focus on protein-based therapeutic and diagnostic products with applications in infectious disease, autoimmune conditions, and immunological deficiency. The company and its management team are key players in the fight against HIV/AIDS, infectious disease, and autoimmune deficiency. Viral Genetics has been working since 1995 to find a cure for HIV/AIDS and is based in Azusa, California.

VRAL develops its products based on thymus nuclear protein (TNP), a processed extract of mammalian thymus tissue. It has developed a lead product, VGV-1, which is a suspension of TNP in alum adjuvant for the treatment of HIV infection and AIDS. VGV-1 is currently in the preclinical stage of development in the United States, but outside of the USA it is in later stage development. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity

Shares of Kosan Biosciences Inc. (NASDAQ: KOSN), a biotechnology company and drug developer that focuses on the genetic manipulation of polyketides, which are used in antibiotics and anticancer drugs, more than tripled recently on the announcement of the signing of a definitive merger agreement with Bristol-Myers Squibb. Under the terms of the agreement, Bristol-Myers Squibb will acquire Kosan for $5.50 per share in cash.

Bristol-Myers Squibb will begin purchasing all of the outstanding shares of Kosan with a net aggregate purchase price of approximately $190 million. This purchase agreement has been unanimously approved by the boards of directors of both companies. Fully committed to the development and commercialization of its pre-clinical portfolio, Kosan Biosciences believes that this acquisition represents a timely and unique opportunity to place the company’s clinical and pre-clinical programs and technology assets into the hands of a world-class oncology company.

Through this acquisition, Kosan Biosciences has granted to